Muutke küpsiste eelistusi

E-raamat: Design and Analysis of Clinical Trials for Predictive Medicine

Edited by (The Institute of Statistical Mathematics, Midori-cho, Tachikawa, Tokyo, Japan), Edited by (Founder of IDDI, Belgium.), Edited by
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 62,39 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Specialists in biostatistics and related fields offer a systematic account of all stages of clinical trials in the co-development of therapeutics and diagnostics for medicine to predict a patient's response to various treatments before the treatment is applied. After introductory overviews, they cover early clinical trails using biomarkers, phase III randomized clinical trials using biomarkers, analyzing high-dimensional data and genomic signature developments, randomized trials with biomarker development and validation, and evaluating surrogate biomarkers. Annotation ©2015 Ringgold, Inc., Portland, OR (protoview.com)

An emerging clinical trials paradigm for predictive medicine involves the development of molecular diagnostics to enable the prediction of the effects of treatment or outcomes of individual patients. This book offers statistical guidance on conducting clinical trials for predictive medicine. It covers statistical topics relevant to the main clinical research phases for developing molecular diagnostics and therapeutics. The book explains how to identify molecular biomarkers using DNA microarrays, validate the developed biomarkers, and confirm their clinical utility in randomized clinical trials.

Arvustused

"To say this is an extremely timely book would be a gross understatement. The editors have assembled an impressive series of articles that address many of the major methodological issues confronting researchers who are attempting to not only identify valuable medical treatments but to determine which subsets of patients will benefit from these treatments. These issues are particularly important in cancer research, where treatments are often burdensome, toxic, and expensive; one does not want to treat large numbers of patients when only a few will benefit [ this] would be a very valuable resource for anyone in, or moving into, the area of clinical trials for developing targeted therapies. Because the chapters steer away from highly technical discussions, I would recommend this book to clinicians as well as statisticians who are working in this challenging and developing area of research." -Susan Ellenberg, Journal of the ~American Statistical Association

"Design and Analysis of Clinical Trials for Predictive Medicine addresses a necessity for precision medicine: identifying and testing molecular biomarkers for their ability to predict the effect of treatments on specific patient populations." ~Journal of Clinical Research Best Practices, December 2015

" a very good collection of relevant topics and methods, which have been published and applied in the field of personalized medicine from a clinical development perspective. The editors of this book are experts in the field and have published extensively on these topics. a useful reference for biostatisticians and researchers involved in the design and analyses of biomarker integrated clinical trials." ~Arunava Chakravartty, Journal of Biopharmaceutical Statistics

" a useful resource for clinical biostatisticians, researchers focusing on predictive medicine, clinical investigators, translational scientists, and graduate biostatistics students."

Preface xi
Editors xiii
Contributors xv
Section I Introductory Overview
1 Clinical Trials for Predictive Medicine: New Paradigms and Challenges
3(8)
Richard Simon
Shigeyuki Matsui
Marc Buyse
2 An Industry Statistician's Perspective on Personalized Health Care Drug Development
11(22)
Jane Fridlyand
Ru-Fang Yeh
Howard Mackey
Thomas Bengtsson
Paul Delmar
Greg Spaniolo
Grazyna Lieberman
3 Analytical Validation of In Vitro Diagnostic Tests
33(20)
Robert Becker, Jr.
Section II Early Clinical Trials Using Biomarkers
4 Phase I Dose-Finding Designs and Their Applicability to Targeted Therapies
53(18)
Takashi Daimon
Akihiro Hirakawa
Shigeyuki Matsui
5 An Overview of Phase II Clinical Trial Designs with Biomarkers
71(18)
Lisa McShane
Sally Hunsberger
6 Bayesian Adaptive Methods for Clinical Trials of Targeted Agents
89(22)
Peter Thall
7 Outcome-Adaptive Randomization in Early Clinical Trials
111(18)
Edward Korn
Boris Freidlin
8 Challenges of Using Predictive Biomarkers in Clinical Trials
129(18)
Sumithra Mandrekar
Daniel Sargent
Section III Phase III Randomized Clinical Trials Using Biomarkers
9 Comparison of Randomized Clinical Trial Designs for Targeted Agents
147(18)
Antje Hoering
Mike LeBlanc
John Crowley
10 Phase III All-Comers Clinical Trials with a Predictive Biomarker
165(22)
Shigeyuki Matsui
Yuki Choai
Takahiro Nonaka
11 Evaluation of Clinical Utility and Validation of Gene Signatures in Clinical Trials
187(20)
Stefan Michiels
Federico Rotolo
Section IV Analysis of High-Dimensional Data and Genomic Signature Developments
12 Statistical Issues in Clinical Development and Validation of Genomic Signatures
207(20)
Shigeyuki Matsui
13 Univariate Analysis for Gene Screening: Beyond Multiple Testing
227(26)
Hisashi Noma
Shigeyuki Matsui
14 Statistical and Machine-Learning Methods for Class Prediction in High Dimension
253(18)
Osamu Komori
Shinto Eguchi
15 Survival Risk Prediction Using High-Dimensional Molecular Data
271(24)
Harald Binder
Thomas Gerds
Martin Schumacher
Section V Randomized Trials with Biomarker Development and Validation
16 Adaptive Clinical Trial Designs with Biomarker Development and Validation
295(20)
Boris Freidlin
Richard Simon
17 Development and Validation of Continuous Genomic Signatures in Randomized Clinical Trials
315(18)
Shigeyuki Matsui
Section VI Evaluation of Surrogate Biomarkers
18 Biomarker-Based Surrogate Endpoints
333(38)
Marc Buyse
Tomasz Burzykowski
Geert Molenberghs
Ariel Alonso
Index 371
Shigeyuki Matsui is a professor in the Department of Biostatistics at Nagoya University Graduate School of Medicine in Japan. He is also a visiting professor at the Institute of Statistical Mathematics. Dr. Matsui has served as council and nominating committee member of the International Biometric Society. He is currently council of the Biometric Society of Japan (BSJ) and editor-in-chief of the Japanese Journal of Biometrics. He is the recipient of the 2014 Award from the BSJ. Dr. Matsui is also a frequent reviewer commissioned by government and advisor to pharmaceutical companies in Japan. He holds degrees in engineering from the Tokyo University of Science in Japan.

Marc E. Buyse is the founder of the International Drug Development Institute in Louvain-la-Neuve, Belgium and of CluePoints Inc. in Cambridge, Massachusetts. He is also an associate professor of biostatistics at Hasselt University in Belgium. He was president of the International Society for Clinical Biostatistics, president of the Quetelet Society, and fellow of the Society for Clinical Trials. He worked at the European Organization for Research and Treatment of Cancer in Brussels and at the Dana Farber Cancer Institute in Boston. He holds degrees in engineering and statistics from Brussels University, management from the Cranfield School of Management in the UK, and a doctorate in biostatistics from Harvard University.

Richard M. Simon is chief of the Biometric Research Branch at the National Cancer Institute in Bethesda, Maryland. He leads a multidisciplinary group of scientists developing and applying methods for the application of genomics to cancer therapeutics. Dr. Simon is the architect of BRB-ArrayTools software used for the analysis of microarray and digital expression, copy number, and methylation data. He is the recipient of the 2013 Karl E. Peace Award for Outstanding Statistical Contributions for the Betterment of Society and is the author or coauthor of more than 450 publications.